Osteoprotegerin is associated with depletion of circulating endothelial progenitor cells and elevation in pulmonary arterial pressure in patients with systolic heart failure

References

• Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 128:240–327.
   Google Scholar
• Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O’Donnell C, Roger V, Sorlie P. Steinberger J, Thom T, Wilson M, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25–146.
   Google Scholar
• Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53:1119–26.
   Google Scholar
• Ben Driss A, Devaux C, Henrion D, Duriez M, Thuillez C, Levy BI, Michel JB. Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure. Circulation 2000; 101:2764–70.
   Google Scholar
• Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. aCirculation 2000; 102:1718–23.
   Google Scholar
• Yin J, Kukucka M, Hoffmann J, Sterner-Kock A, Burhenne J, Haefeli WE, Kuppe H, Kuebler WM. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail 2011; 4: 198–206.
   Google Scholar
• Abramowicz MJ, Van Haecke P. Demedts M, Delcroix M. Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Eur Respir J2003; 22:560–2.
   Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lathy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P. Sander S, Van G, Tarpley J, Derby P. Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309–19.
   Google Scholar
• Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15:2–12.
   Google Scholar
• Lawrie A, Waterman E, Southwood M, Evans D, Suntharalingam J, Francis S, Crossman D, Croucher P. Morrell N, Newman C. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol 2008; 172: 256–64.
   Google Scholar
• Kim JY, Park YJ, Kim KJ, Choi JJ, Kim WU, Cho CS. Osteoprotegerin causes apoptosis of endothelial progenitor cells by induction of oxidative stress. Arthritis Rheum 2013; 65: 2172–82.
   Google Scholar
• Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348:593–600.
   Google Scholar
• Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S. Vascular trauma induces rapid but transient mobilization of VEGFR2 +AC133 + endothelial precursor cells. Circ Res 2001; 88: 167–74.
   Google Scholar
• Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo DW, Asa hara T, Isner JM. Statin therapy accelerate re-endothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105: 3017–24.
   Google Scholar
• Junhui Z, Xingxiang W, Guosheng F, Yunpeng S, Furong Z, Junzhu C. Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. RespiratoryMedicine 2008; 102: 1073–9.
   Google Scholar
• Yue WS, Wang M, Yan GH, Yiu KH, Yin L, Lee SW, Siu CW, Tse HF. Smoking is associated with depletion of circulating endothelial progenitor cells and elevated pulmonary artery systolic pressure in patients with coronary artery disease. Am J Cardiol 2010; 106:1248–54.
   Google Scholar
• Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1–7.
   Google Scholar
• Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T.Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000; 97:3422–7.
   Google Scholar
• Chen JZ, Zhu JH, Wang XX, Zhu JH, Xie XD, Sun J, Shang YP, Guo XG, Dai HM, Hu SJ. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol 2004; 36:233–9.
   Google Scholar
• Strehlow K, Werner N, Berweiler J, Link A, Dirnagl U, Priller J, Laufs K, Ghaeni L, Milosevic M, B8hm M, Nickenig G. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 2003; 107: 3059–65.
   Google Scholar
• Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37: 183–8.
   Google Scholar
• Mann DL. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev 2001; 6: 71–80.
   Google Scholar
• Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Froland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heartfailure. Circulation 2005; 111: 2461–8.
   Google Scholar
• Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 2008; 29:403–40.
   Google Scholar
• Kiechl S, Werner P. Knoflach M, Furtner M, Willeit J, Schett G. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006; 4: 801–11.
   Google Scholar
• Andersen GO, Knudsen EC, Aukrust P. Yndestad A, Ole E, Muller C, Seljeflot I, Ueland T. Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart 2011; 97:460–5.
   Google Scholar
• Steinmetz M, Skowasch D, Wernert N, Welsch U, Preusse CJ, Welz A, Nickenig G, Bauriedel G. Differential profile of the OPG/RANKL/RANK system in degenerative aortic native and bioprosthetic valves. J Heart Valve Dis 2008; 17: 187–93.
   Google Scholar
• Ndip A, Williams A, Jude EB, Serracino-Inglott F, Richardson S, Smyth JV, Boulton AJ, Alexander MY. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes 2011; 60:2187–96.
   Google Scholar
• Chang YH, Lin KD, He SR, Hsieh MC, Hsiao JY, Shin SJ. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy. Metabolism 2011; 60:1064–9.
   Google Scholar
• Roysland R, Masson S, Omland T, Milani V. Bjerre M, Flyvbjerg A, Di Tano G, Misuraca G, Maggioni AP, Tognoni G, Tavazzi L, Latini R; GISSI-HF Investigators. Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. Am Heart J2010; 160: 286–93.
   Google Scholar
• Ueland T, Dahl CP, Kjekshus J, Hulthe J, Böhm M, Mach F, Goudev A, Lindberg M, Wikstrand J, Aukrust P. Gullestad L. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail 2011; 4: 145–52.
   Google Scholar
• Ueland T, Yndestad A, Dahl CP, Gullestad L, Aukrust P.TNF revisited: Osteoprotegerin and TNF-related molecules in heart failure. Curr Heart Fail Rep 2012; 9:92–100.
   Google Scholar
• Montagnana M, Lippi G, Danese E, Guidi GC.The role of osteoprotegerin in cardiovascular disease. Ann Med 2013; 45: 254–64.
   Google Scholar
• Condliffe R, Pickworth JA, Hopkinson K, Walker SJ, Hameed AG, Suntharaligam J, Soon E, Treacy C, Pepke-Zaba J, Francis SE, Crossman DC, Newman CM, Elliot CA, Morton AC, Morrell NW, Kiely DG, Lawrie A. Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension. Pulm Circ 2012; 2:21–7.
   Google Scholar
• Brun H, Holmstrom H, Thaulow E, Dame’s JK, Yndestad A, Aukrust P. Ueland T. Patients with pulmonary hypertension related to congenital systemic-to pulmonary shunts are characterized by inflammation involving endothelial cell activation and platelet-mediated inflammation. Congenit Heart Dis 2009; 4: 153–9.
   Google Scholar
• Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349–53.
   Google Scholar
• Cracowski JL, Yaici A, Sitbon O, Reynaud-Gaubert M, Renversez JC, Pison C, Faure P. Cracowski C, Chouri N, Chaouat A, Chabot F, Schwedhelm E, Maas R, Degano B, Mornex JF, Humbert M. Biomarkers as prognostic factors in pulmonary arterial hypertension. Rationale and study design. Rev Mal Respir 2004; 21:1137–43.
   Google Scholar
• Friedewald VE, Hare JM, Miller LW, Walpole HT Jr, Willerson JT, Roberts WC. The editor’s roundtable: advances in stem cell therapy for treatment of cardiovascular disease. Am J Cardiol 2012; 110: 807–16.
   Google Scholar